Xenon Pharmaceuticals (XENE) Non Operating Income (2021 - 2026)

Xenon Pharmaceuticals (XENE) has reported Non Operating Income for 6 consecutive years, with $7.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non Operating Income fell 8.17% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $27.5 million (down 26.58% YoY), while the FY2025 annual figure was $28.2 million, down 31.07% from the prior year.
• Non Operating Income advanced to $7.5 million in Q1 2026 per XENE's latest filing, from $5.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $11.5 million in Q1 2024 and bottomed at -$2.7 million in Q1 2022.
• Historically, Non Operating Income has averaged $6.6 million across 5 years, with a median of $7.6 million in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income surged 3023.55% — and 2025, when it plunged 42.11%.
• Xenon Pharmaceuticals' Non Operating Income stood at $7.1 million in 2022, then rose by 23.63% to $8.7 million in 2023, then fell by 9.18% to $7.9 million in 2024, then sank by 36.51% to $5.0 million in 2025, then surged by 47.8% to $7.5 million in 2026.
• Business Quant data shows XENE's Non Operating Income at $7.5 million in Q1 2026, $5.0 million in Q4 2025, and $6.1 million in Q3 2025.